### Puma Biotechnology Earnings Call Commercial Update



August 6, 2020






# **Forward-Looking Safe Harbor Statement**

This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward-looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. ("Puma"). Forward–looking statements involve risks and uncertainties that could cause Puma's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements, including, but not limited to, any adverse impact on Puma's business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and other risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Puma's Annual Report on Form 10-K for the year ended December 31, 2019, Puma's Quarterly Report on Form 10-Q for the period ended June 30, 2020 and subsequent reports. You are cautioned not to place undue reliance on these forward-looking statements as representing Puma's views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.




#### **PUMA's Pharmacy and Distributor Network**






#### ~\$48.8 Million Net NERLYNX Revenue in Q2'2020






#### ~3,700 Commercial bottles were sold in Q2'20



Includes Commercial SP and SD



#### ~31% of Patients in Q2'20 Started NERLYNX at a Reduced Dose



Reduced Dose defined as fewer than 6 pills per day



## **Rest of World Partnerships – Timelines**

Region	Partner	Regulatory / Launch Milestones
Australia / SE Asia	Specialised * Therapeutics	<ul> <li>March 2019 – Approved in Australia</li> <li>December 2019 Approved in Singapore</li> <li>Q2/Q3 2020 - Approved in Brunei, Malaysia, New Zealand</li> </ul>
Israel	Delivering Innovative Healthcare	• Q1 2020 - Launched
Canada	<b></b> <i><b>•</b><i>Knight</i></i>	<ul> <li>July 2019 – Approved</li> </ul>
Greater China	CP□bridge 北海康成	<ul> <li>November 2019 – Approved in Hong Kong</li> <li>April 2020 – Approved in China</li> <li>August 2020 – Approved in Taiwan</li> </ul>
Latin America	PINT PHARMA	<ul> <li>Q1 2020 – Argentina-Launched</li> <li>Q2 2020 – Approved in Chile</li> <li>2H 2020 – Ecuador</li> <li>2021 – Brazil, Colombia, Mexico, Peru</li> </ul>
Europe Middle East North and West Africa South Africa Turkey	S Pierre Fabre	<ul> <li>Launch Timelines</li> <li>Q4 2019 – Germany-Launched</li> <li>Q4 2019 – United Kingdom-Launched</li> <li>Q4 2019 – Austria-Launched</li> <li>Q1 2020 – Sweden Launched</li> <li>Q1 2020 – Approved in Switzerland</li> <li>2020-2023 – Rest of Territory</li> </ul>
South Korea	BIXINK	End of 2020 – NDA Filing

#### Puma Biotechnology Earnings Call Commercial Update



August 6, 2020



